Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-12-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's third board meeting, specifically regarding a stock option incentive plan and the appointment of vice presidents. It references compliance with laws and regulations, and provides formal approval opinions. The document is not a full financial report, earnings release, or regulatory filing but rather a formal board/management related announcement about governance and management decisions. It does not contain financial statements or earnings data, nor is it a report publication announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management appointments and board opinions, confirming this classification.
2019-12-30 Chinese
2018年（第二期）股票期权激励计划预留期权激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of reserved stock option incentive recipients under a 2018 stock option incentive plan for Betta Pharmaceuticals Co., Ltd. It contains detailed names and categories of management and core technical personnel who are recipients of stock options. This is a disclosure related to stock option incentives, which is typically categorized under announcements related to share issues or capital changes. The document is not a full financial report, earnings release, or management discussion. It is not a proxy statement or AGM material. It is a specific announcement about stock option allocations, which fits best under Share Issue/Capital Change (SHA). The document length is about 2,034 characters, which is consistent with an announcement rather than a full report.
2019-12-30 Chinese
关于公司聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 贝达药业股份有限公司 regarding the appointment of senior management personnel, specifically the hiring of two vice presidents. It includes detailed biographies and qualifications of the appointed individuals. There is no financial data, report, or regulatory filing referenced beyond the appointment itself. The content clearly fits the category of announcing changes in senior management rather than financial results, governance rules, or other report types.
2019-12-30 Chinese
第三届监事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the second meeting of the third Supervisory Board of Betta Pharmaceuticals Co., Ltd. It details the approval of the 2018 (second phase) stock option incentive plan reserved options grant, including the verification of the eligibility of the 71 incentive recipients and the voting results. The document is an official announcement of a board/management decision related to stock option incentives, not a full report or financial statement. It does not contain financial data or detailed management discussion but rather the outcome of a board meeting and related approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1621 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2019-12-30 Chinese
浙江天册律师事务所关于公司2018年（第二期）股票期权激励计划预留部分授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the stock option incentive plan reserved portion grant for a company. It details the legal review and approval process of the stock option grant, including board and shareholder meeting approvals, compliance with relevant laws and regulations, and confirmation of the grant date and recipients. The document is not a financial report, earnings release, or management discussion but a legal certification related to a specific corporate action (stock option grant). It does not contain financial statements or management analysis but is a formal legal opinion on the stock option grant process. Therefore, it fits best under Regulatory Filings (RNS) as it is a legal opinion document related to regulatory compliance and corporate governance matters, not a financial report or announcement of voting results or capital changes.
2019-12-30 Chinese
关于公司2018年（第二期）股票期权激励计划预留股票期权授予的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the granting of reserved stock options under its 2018 (second phase) stock option incentive plan. It details the approval process, the number of options granted, the exercise price, the conditions for granting, and the impact on financials. It is a formal disclosure about a stock option incentive plan grant, including board and supervisory approvals, independent director opinions, and legal opinions. This type of document is a capital/financing update related to equity incentives and stock option grants, not a full financial report or earnings release. It is not a regulatory filing or announcement of a report publication, but a substantive announcement about capital structure changes via stock options. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2019-12-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.